Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | June 12, 2024 | June 14, 2024 |
| Travere Therapeutics, Inc.TVTX · Entity 1562 | Director | May 11, 2022 | May 13, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date June 12, 2024 · Filed June 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 70,159 |
Reported balance
After 2024-06-12 transaction · row 1
1 source rowRow 1 · 2024-06-12 · Grant · Acquired 6,820 · Balance 70,159 F1: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant. |
| Automatic Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $6.30 · Expires 2034-06-12 | Direct | 49,933 |
Reported balance
After 2024-06-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-12 · Grant · Acquired 49,933 · Balance 49,933 F2: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 2,500 |
Reported balance
Holding disclosure · report date 2024-06-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,500 |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
F2: Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.
Travere Therapeutics, Inc.
Report date May 11, 2022 · Filed May 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 146,919 |
Reported balance
After 2022-05-11 transaction · row 1
1 source rowRow 1 · 2022-05-11 · Sale · Disposed 2,575 · Balance 146,919 F1: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Acer Therapeutics Inc.
Report date November 17, 2023 · Filed November 20, 2023
Section 16 reporting ended · disclosed 2023-11-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par value per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-17 transaction · row 1
1 source rowRow 1 · 2023-11-17 · Disposition to issuer · Disposed 483,741 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 30, 2023, by and among Acer Therapeutics Inc., a Delaware corporation ("Issuer"), Zevra Therapeutics, Inc., a Delaware corporation ("Zevra"), and Aspen Z Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Zevra ("Merger Sub"), effective November 17, 2023 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly-owned subsidiary of Zevra. F2: Pursuant to the Merger Agreement, at the Effective Time, each share of Issuer common stock, $0.0001 par value per share, issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.1210 fully paid and non-assessable shares of common stock of Zevra, par value $0.0001 per share, and (ii) one non-transferable contingent value right issued by Zevra, which entitles the holder to potentially receive their pro rata portion of contingent payments of (A) up to $76 million in cash upon the achievement of certain commercial and regulatory milestones for certain of Acer's products and (B) additional cash of an indeterminate amount, subject to achievement of milestones related to Acer's early-phase emetine program, and otherwise subject to and in accordance with the terms and conditions of the Contingent Value Rights Agreement, dated as of November 17, 2023, by and among Zevra, Computershare Inc. and Computershare Trust Company. F3: (Continued From Footnote 2) At the Effective Time, the closing price of one share of Zevra common stock was $4.34. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 30, 2023, by and among Acer Therapeutics Inc., a Delaware corporation ("Issuer"), Zevra Therapeutics, Inc., a Delaware corporation ("Zevra"), and Aspen Z Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Zevra ("Merger Sub"), effective November 17, 2023 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly-owned subsidiary of Zevra.
F2: Pursuant to the Merger Agreement, at the Effective Time, each share of Issuer common stock, $0.0001 par value per share, issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.1210 fully paid and non-assessable shares of common stock of Zevra, par value $0.0001 per share, and (ii) one non-transferable contingent value right issued by Zevra, which entitles the holder to potentially receive their pro rata portion of contingent payments of (A) up to $76 million in cash upon the achievement of certain commercial and regulatory milestones for certain of Acer's products and (B) additional cash of an indeterminate amount, subject to achievement of milestones related to Acer's early-phase emetine program, and otherwise subject to and in accordance with the terms and conditions of the Contingent Value Rights Agreement, dated as of November 17, 2023, by and among Zevra, Computershare Inc. and Computershare Trust Company.
F3: (Continued From Footnote 2) At the Effective Time, the closing price of one share of Zevra common stock was $4.34.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 02, 2020 Filed Dec 5, 2020 00:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 7,891 | $23.43 | $184,849.04 |
DisclosureSEC source: 0001209191-20-061869 · doc4.xml · nonDerivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,216 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.42 to $23.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 21:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,956 | $5.11 | $9,995.16 |
DisclosureSEC source: 0001127602-20-030289 · form4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,569 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| November 19, 2020 Filed Dec 5, 2020 00:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-061869 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,107 Read SEC document |
| November 06, 2020 Filed Nov 7, 2020 01:56 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 20,625 | $23.00 | $474,375.00 |
DisclosureSEC source: 0001209191-20-057381 · doc4.xml · nonDerivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,107 F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| November 05, 2020 Filed Nov 7, 2020 01:56 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 2,500 | $21.26 | $53,150.00 |
DisclosureSEC source: 0001209191-20-057381 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,732 F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 20:36 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 2,409 | $4.15 | $9,997.35 |
DisclosureSEC source: 0001127602-20-024642 · form4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,613 F1 · security: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $10,000. Read SEC document |
| August 05, 2020 Filed Aug 6, 2020 20:07 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 2,500 | $19.68 | $49,200.00 |
DisclosureSEC source: 0001209191-20-045456 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,232 F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| July 24, 2020 Filed Jul 28, 2020 09:02 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | PurchaseCommon Stock | 45,000 | $3.50 | $157,500.00 |
DisclosureSEC source: 0001209191-20-043805 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,905 Read SEC document |
| June 25, 2020 Filed Jun 30, 2020 01:02 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 10,000 | $20.00 | $200,000.00 |
DisclosureSEC source: 0001209191-20-039338 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,732 F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:24 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,112 | $4.50 | $4,998.44 |
DisclosureSEC source: 0001127602-20-018719 · form4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,204 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000. Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:00 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 9,000 | $0.00 Strike: $15.43 | $0.00 |
DisclosureSEC source: 0001209191-20-030744 · doc4.xml · derivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-05-14 Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:00 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030744 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,732 Read SEC document |
| May 14, 2020 Filed May 15, 2020 00:59 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 3,062 | $15.09 | $46,205.58 |
DisclosureSEC source: 0001209191-20-029410 · doc4.xml · nonDerivative · entry 3 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,732 F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| May 13, 2020 Filed May 15, 2020 00:59 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 4,063 | $16.41 | $66,673.83 |
DisclosureSEC source: 0001209191-20-029410 · doc4.xml · nonDerivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,794 F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| May 12, 2020 Filed May 14, 2020 20:18 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 40,000 | $0.00 Strike: $5.41 | $0.00 |
DisclosureSEC source: 0001127602-20-016559 · form4.xml · derivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-05-12 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:59 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 1,000 | $17.16 | $17,160.00 |
DisclosureSEC source: 0001209191-20-029410 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,857 F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| May 05, 2020 Filed May 6, 2020 20:09 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 2,500 | $15.88 | $39,700.00 |
DisclosureSEC source: 0001209191-20-027448 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,857 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 05, 2020 Filed Mar 10, 2020 01:03 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 4,359 | $15.36 | $66,938.55 |
DisclosureSEC source: 0001209191-20-017537 · doc4.xml · nonDerivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,357 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 05, 2020 Filed Mar 10, 2020 01:03 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 12,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-017537 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,716 F1 · kind: On May 10, 2018, the reporting person was granted performance restricted stock units (PRSUs) covering 24,500 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On March 5, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 190 patients in the sparsentan DUPLEX Phase 3 Study had been enrolled. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 21:59 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,666 | $3.00 | $4,998.00 |
DisclosureSEC source: 0001127602-20-009094 · form4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,092 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000. Read SEC document |
| February 05, 2020 Filed Feb 8, 2020 00:38 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 2,500 | $16.62 | $41,550.00 |
DisclosureSEC source: 0001209191-20-007720 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,466 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 16:13 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | GrantStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001209191-20-000860 · doc4.xml · derivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-01-02 F1 · derivative.exercise_date: The option vests and becomes exercisable in full on January 2, 2021. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 22:14 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,754 | $2.85 | $4,998.90 |
DisclosureSEC source: 0001127602-19-034168 · form4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,426 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000. Read SEC document |
| November 29, 2019 Filed Nov 30, 2019 02:27 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 5,000 | $13.91 | $69,552.50 |
DisclosureSEC source: 0001209191-19-058446 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,966 F1 · price: The price reported in Column 4 is a weighted average price and includes 4,933 shares sold at $13.91 per share and 67 shares sold at $13.95 per share. Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 21:01 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | PurchaseCommon Stock | 15,000 | $1.45 | $21,750.00 |
DisclosureSEC source: 0001127602-19-033001 · form4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,672 Read SEC document |
| September 01, 2019 Filed Sep 4, 2019 20:14 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 1,672 | $2.99 | $4,999.28 |
DisclosureSEC source: 0001127602-19-027867 · form4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,672 F1 · security: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000. Read SEC document |
| July 03, 2019 Filed Jul 5, 2019 16:08 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | PurchaseCommon Stock | 5,000 | $3.72 | $18,581.00 |
DisclosureSEC source: 0001209191-19-041332 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,905 Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:13 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001127602-19-020302 · form4.xml · derivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-05-29 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Read SEC document |
| May 22, 2019 Filed May 24, 2019 20:20 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | PurchaseCommon Stock | 3,000 | $3.57 | $10,710.00 |
DisclosureSEC source: 0001127602-19-019891 · form4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| May 15, 2019 Filed May 17, 2019 01:34 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 1,838 | $17.82 | $32,753.16 |
DisclosureSEC source: 0001209191-19-030657 · doc4.xml · nonDerivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,966 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.69 to $17.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 14, 2019 Filed May 17, 2019 01:34 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 1,838 | $17.79 | $32,698.02 |
DisclosureSEC source: 0001209191-19-030657 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,804 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.74 to $17.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:32 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 8,000 | $0.00 Strike: $17.94 | $0.00 |
DisclosureSEC source: 0001209191-19-029151 · doc4.xml · derivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2029-05-07 Read SEC document |
| May 08, 2019 Filed May 11, 2019 00:32 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029151 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,642 Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 20:18 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | PurchaseCommon Stock | 2,000 | $8.30 | $16,600.00 |
DisclosureSEC source: 0001127602-19-011361 · form4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · price: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $8.21 to $8.38. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 01:47 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 1,065 | $21.50 | $22,897.50 |
DisclosureSEC source: 0001209191-19-009924 · doc4.xml · nonDerivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,642 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 11, 2019 Filed Feb 14, 2019 01:47 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 1,065 | $21.38 | $22,769.70 |
DisclosureSEC source: 0001209191-19-009924 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,707 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 13:50 UTC | Acer Therapeutics Inc. ACER · Entity 108116 | GrantEmployee Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $24.46 | $0.00 |
DisclosureSEC source: 0001209191-19-007239 · doc4.xml · derivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2029-02-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in full on February 1, 2020. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 18:23 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantNon-Qualified Stock Option · Derivative | 25,000 | $0.00 Strike: $8.62 | $0.00 |
DisclosureSEC source: 0001127602-19-001582 · form4.xml · derivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-01-04 F1 · shares: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan. Read SEC document |
| December 21, 2018 Filed Dec 22, 2018 01:20 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 900 | $22.35 | $20,111.04 |
DisclosureSEC source: 0001209191-18-064022 · doc4.xml · nonDerivative · entry 3 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,772 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.2850 to $22.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 21, 2018 Filed Dec 22, 2018 01:20 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 5,288 | $21.69 | $114,718.40 |
DisclosureSEC source: 0001209191-18-064022 · doc4.xml · nonDerivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,672 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.22 to $22.1975, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 20, 2018 Filed Dec 22, 2018 01:20 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 6,188 | $21.97 | $135,958.40 |
DisclosureSEC source: 0001209191-18-064022 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,960 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.82 to $22.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 18, 2018 Filed Dec 21, 2018 00:56 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 20,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-063772 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,148 F1 · kind: On May 17, 2017, the reporting person was granted performance restricted stock units (PRSUs) covering 41,250 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On December 18, 2018, a portion of the PRSUs vested upon the Issuer's confirmation that the Phase 3 FORT study of fosmetpantotenate in PKAN had fully enrolled. Read SEC document |
| December 07, 2018 Filed Dec 8, 2018 02:15 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 10 | $24.04 | $240.37 |
DisclosureSEC source: 0001209191-18-061669 · doc4.xml · nonDerivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,523 Read SEC document |
| November 29, 2018 Filed Dec 8, 2018 02:15 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GiftCommon Stock | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-061669 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,533 Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 00:16 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 1,086 | $24.75 | $26,880.02 |
DisclosureSEC source: 0001209191-18-059063 · doc4.xml · nonDerivative · entry 4 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,283 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.67 to $24.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 15, 2018 Filed Nov 17, 2018 00:16 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 4,464 | $24.21 | $108,088.62 |
DisclosureSEC source: 0001209191-18-059063 · doc4.xml · nonDerivative · entry 3 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,369 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.65 to $24.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 00:16 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 600 | $24.58 | $14,745.00 |
DisclosureSEC source: 0001209191-18-059063 · doc4.xml · nonDerivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,833 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.38 to $24.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 14, 2018 Filed Nov 17, 2018 00:16 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 4,950 | $23.63 | $116,989.79 |
DisclosureSEC source: 0001209191-18-059063 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,433 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.35 to $24.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 09, 2018 Filed Nov 15, 2018 01:42 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 18,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-058647 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,383 F1 · kind: On July 1, 2015, the reporting person was granted performance restricted stock units (PRSUs) covering 37,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On November 9, 2018, a portion of the PRSUs vested upon the Issuer's confirmation that the US Food and Drug Administration had accepted for review a New Drug Application filed by the Issuer's partner. Read SEC document |
| August 31, 2018 Filed Aug 31, 2018 23:54 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 12,000 | $0.00 Strike: $8.70 | $0.00 |
DisclosureSEC source: 0001209191-18-049134 · doc4.xml · derivative · entry 3 ASELAGE STEVE · CIK 0001221599 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2023-12-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.